HRP20191248T1 - Kombinirana terapija za liječenje karcinoma jajnika - Google Patents
Kombinirana terapija za liječenje karcinoma jajnika Download PDFInfo
- Publication number
- HRP20191248T1 HRP20191248T1 HRP20191248TT HRP20191248T HRP20191248T1 HR P20191248 T1 HRP20191248 T1 HR P20191248T1 HR P20191248T T HRP20191248T T HR P20191248TT HR P20191248 T HRP20191248 T HR P20191248T HR P20191248 T1 HRP20191248 T1 HR P20191248T1
- Authority
- HR
- Croatia
- Prior art keywords
- bevacizumab
- patient
- platinum
- use according
- resistant
- Prior art date
Links
- 206010033128 Ovarian cancer Diseases 0.000 title claims 6
- 238000011282 treatment Methods 0.000 title claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 title claims 2
- 238000002648 combination therapy Methods 0.000 title 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 20
- 229960000397 bevacizumab Drugs 0.000 claims 13
- 229910052697 platinum Inorganic materials 0.000 claims 10
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims 4
- 229930012538 Paclitaxel Natural products 0.000 claims 4
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 claims 4
- 229960001592 paclitaxel Drugs 0.000 claims 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 4
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 3
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 206010003445 Ascites Diseases 0.000 claims 1
- 230000003187 abdominal effect Effects 0.000 claims 1
- 238000011394 anticancer treatment Methods 0.000 claims 1
- 201000001343 fallopian tube carcinoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000002524 peritoneal carcinoma Diseases 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q30/00—Commerce
- G06Q30/02—Marketing; Price estimation or determination; Fundraising
- G06Q30/0241—Advertisements
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q90/00—Systems or methods specially adapted for administrative, commercial, financial, managerial or supervisory purposes, not involving significant data processing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Business, Economics & Management (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Strategic Management (AREA)
- Finance (AREA)
- Development Economics (AREA)
- Economics (AREA)
- Physics & Mathematics (AREA)
- General Business, Economics & Management (AREA)
- Accounting & Taxation (AREA)
- Theoretical Computer Science (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Marketing (AREA)
- Game Theory and Decision Science (AREA)
- Entrepreneurship & Innovation (AREA)
- Reproductive Health (AREA)
- Dispersion Chemistry (AREA)
Claims (10)
1. Bevacizumab, naznačen time, da je za uporabu u postupku liječenja pacijentice kojoj je dijagnosticiran epitelni karcinom jajnika rezistentan na platinu (EOC), karcinom Fallopijevih cijevi rezistentan na platinu (FTC) ili primarni peritonealni karcinom rezistentan na platinu (PPC), pri čemu postupak obuhvaća primjenu učinkovite doze bevacizumaba i paklitaksela spomenutoj pacijentici, gdje je spomenuta pacijentica primila dva režima liječenja protiv karcinoma ili manje od toga, dok spomenuti tretman produljuje preživljenje bez napredovanja bolesti za spomenutu pacijenticu u usporedbi s pacijenticom koja ima epitelni karcinom jajnika rezistentan na platinu (EOC), karcinom Fallopijevih cijevi rezistentan na platinu (FTC) ili primarni peritonealni karcinom rezistentan na platinu (PPC), a koja prima samo paklitaksel.
2. Bevacizumab za uporabu prema patentnom zahtjevu 1, naznačen time, da spomenuta pacijentica nije refraktarna na prethodnu terapiju platinom.
3. Bevacizumab za uporabu prema patentnom zahtjevu 1, naznačen time, da spomenuta pacijentica ima bolest mjerljivu prema RECIST 1.0 ili bolest procjenjivu prema CA-125 prema GCIG kriterijima.
4. Bevacizumab za uporabu prema patentnom zahtjevu 1, naznačen time, da spomenuta pacijentica ima status ECOG performansa od 0 do 2 te životni vijek od barem 12 tjedana.
5. Bevacizumab za uporabu prema patentnom zahtjevu 1, naznačen time, da se spomenuta učinkovita količina paklitaksela primjenjuje pri dozi od 80 mg/m2 kao jednosatna infuzija na dane 1, 8, 15 i 22, svaka 4 tjedna.
6. Bevacizumab za uporabu prema patentnom zahtjevu 1, naznačen time, da je učinkovita količina bevacizumaba 10 mg/kg intravenski svaka dva tjedna ili 15 mg/kg intravenski svaka tri tjedna.
7. Bevacizumab za uporabu prema patentnom zahtjevu 6, naznačen time, da se učinkovita količina bevacizumaba početno daje intravenski tijekom 90 minuta s posljedičnim infuzijama tijekom 60 minuta, a potom 30 minuta.
8. Bevacizumab za uporabu prema patentnom zahtjevu 1, naznačen time, da spomenuta pacijentica ima razdoblje bez primanja platine (PFI - eng. Platinum free interval) kraće od 3 mjeseca.
9. Bevacizumab za uporabu prema patentnom zahtjevu 1, naznačen time, da spomenuta pacijentica ima abdominalni ascites.
10. Bevacizumab za uporabu prema patentnom zahtjevu 1, naznačen time, da spomenuti tretman poboljšava objektivnu stopu odgovora spomenute pacijentice (ORR – eng. objective response rate) u usporedbi s pacijenticom koja ima karcinom jajnika otporan na platinu, a koja prima samo paklitaksel.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261610128P | 2012-03-13 | 2012-03-13 | |
| US201261653598P | 2012-05-31 | 2012-05-31 | |
| US201261672987P | 2012-07-18 | 2012-07-18 | |
| PCT/EP2013/054818 WO2013135602A2 (en) | 2012-03-13 | 2013-03-11 | Combination therapy for the treatment of ovarian cancer |
| EP13708435.6A EP2825558B1 (en) | 2012-03-13 | 2013-03-11 | Combination therapy for the treatment of ovarian cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191248T1 true HRP20191248T1 (hr) | 2019-10-18 |
Family
ID=47844333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191248TT HRP20191248T1 (hr) | 2012-03-13 | 2019-07-11 | Kombinirana terapija za liječenje karcinoma jajnika |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US20150098988A1 (hr) |
| EP (2) | EP3553083A1 (hr) |
| JP (2) | JP6563197B2 (hr) |
| KR (1) | KR102082363B1 (hr) |
| CN (1) | CN104334577A (hr) |
| AR (1) | AR090313A1 (hr) |
| AU (2) | AU2013231410B2 (hr) |
| BR (1) | BR112014018964A2 (hr) |
| CA (2) | CA2860941C (hr) |
| CO (1) | CO7000770A2 (hr) |
| CR (1) | CR20140400A (hr) |
| CY (1) | CY1121821T1 (hr) |
| DK (1) | DK2825558T3 (hr) |
| EA (1) | EA201400996A1 (hr) |
| ES (1) | ES2736030T3 (hr) |
| HK (1) | HK1202122A1 (hr) |
| HR (1) | HRP20191248T1 (hr) |
| HU (1) | HUE045445T2 (hr) |
| IL (2) | IL234174B (hr) |
| LT (1) | LT2825558T (hr) |
| MX (1) | MX365139B (hr) |
| PE (1) | PE20141909A1 (hr) |
| PH (1) | PH12014501543A1 (hr) |
| PL (1) | PL2825558T3 (hr) |
| PT (1) | PT2825558T (hr) |
| RS (1) | RS58964B1 (hr) |
| SG (1) | SG11201404417PA (hr) |
| SI (1) | SI2825558T1 (hr) |
| SM (1) | SMT201900389T1 (hr) |
| TW (1) | TW201343178A (hr) |
| WO (1) | WO2013135602A2 (hr) |
| ZA (1) | ZA201404843B (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2758073B1 (en) | 2011-09-23 | 2018-10-31 | OncoMed Pharmaceuticals, Inc. | Vegf/dll4 binding agents and uses thereof |
| WO2013135602A2 (en) | 2012-03-13 | 2013-09-19 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of ovarian cancer |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| JP6967003B2 (ja) * | 2015-09-23 | 2021-11-17 | メレオ バイオファーマ ５ インコーポレイテッド | がんの処置のための方法および組成物 |
| WO2017117464A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| US20200121703A1 (en) * | 2017-06-26 | 2020-04-23 | The Cleveland Clinic Foundation | Cancer treatment |
| EP3758737A4 (en) | 2018-03-02 | 2022-10-12 | Kodiak Sciences Inc. | IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF |
| EP4041312A4 (en) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | METHOD FOR TREATING AN EYE DISORDER |
| CN115814076A (zh) * | 2021-07-01 | 2023-03-21 | 江苏先声药业有限公司 | 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用 |
| CN117940164A (zh) * | 2022-04-26 | 2024-04-26 | 石药集团中奇制药技术（石家庄）有限公司 | 米托蒽醌脂质体联合抗血管生成靶向药治疗卵巢癌的用途 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP0666868B2 (en) | 1992-10-28 | 2006-06-14 | Genentech, Inc. | Use of anti-VEGF antibodies for the treatment of cancer |
| US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| JPH11510170A (ja) | 1995-07-27 | 1999-09-07 | ジェネンテック インコーポレーテッド | タンパク質の処方 |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| US7365166B2 (en) | 1997-04-07 | 2008-04-29 | Genentech, Inc. | Anti-VEGF antibodies |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| DK0973804T3 (da) | 1997-04-07 | 2007-05-07 | Genentech Inc | Anti-VEGF-antistoffer |
| ES2256935T3 (es) | 1997-04-07 | 2006-07-16 | Genentech, Inc. | Anticuerpos humanizadores y procedimiento para producirlos. |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| ATE531812T1 (de) | 1997-12-05 | 2011-11-15 | Scripps Research Inst | Humanisierung von nager-antikörpern |
| EP1140173B2 (en) | 1998-12-22 | 2013-04-03 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists and uses thereof |
| US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| WO2001044463A1 (en) | 1999-12-15 | 2001-06-21 | Genentech, Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| CN101940189A (zh) | 2000-11-30 | 2011-01-12 | 米德列斯公司 | 用于生产人类抗体的转基因转染色体啮齿动物 |
| IL149701A0 (en) | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
| CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
| US20050079574A1 (en) | 2003-01-16 | 2005-04-14 | Genentech, Inc. | Synthetic antibody phage libraries |
| CN1829741A (zh) | 2003-05-30 | 2006-09-06 | 健泰科生物技术公司 | 利用抗－vegf抗体的治疗 |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| BRPI0508761A (pt) | 2004-03-31 | 2007-08-14 | Genentech Inc | anticorpo humanizado, composição que compreende um anticorpo humanizado, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo humanizado, método de tratamento de disfunção tgf-beta, método de detecção de tgf-beta, artigo industrializado e método de tratamento de cáncer |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| SV2006002143A (es) * | 2004-06-16 | 2006-01-26 | Genentech Inc | Uso de un anticuerpo para el tratamiento del cancer resistente al platino |
| US20060009360A1 (en) | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
| HUE039591T2 (hu) | 2004-09-03 | 2019-01-28 | Genentech Inc | Humanizált anti-béta7 antagonisták és alkalmazásaik |
| US20070166388A1 (en) * | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| EP1973951A2 (en) | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| TW200812616A (en) | 2006-05-09 | 2008-03-16 | Genentech Inc | Binding polypeptides with optimized scaffolds |
| AU2007335744A1 (en) * | 2006-12-20 | 2008-06-26 | Alberto A. Gabizon | Method for administration of pegylated liposomal doxorubicin |
| CA2675451A1 (en) | 2007-02-01 | 2008-07-08 | Genentech, Inc. | Combination therapy with angiogenesis inhibitors |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| US20110159080A1 (en) * | 2008-06-03 | 2011-06-30 | Colin Lowery | Composition comprising liposome-entrapped doxorubicin and methods of administration |
| HUE024872T2 (en) | 2008-11-22 | 2016-02-29 | Hoffmann La Roche | Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer |
| US20190185555A1 (en) | 2017-12-19 | 2019-06-20 | Genentech, Inc. | Anti-angiogenesis therapy for the treatment of previously treated breast cancer |
| CN110227154A (zh) | 2010-02-23 | 2019-09-13 | 霍夫曼-拉罗奇有限公司 | 用于治疗卵巢癌的抗血管发生疗法 |
| WO2013135602A2 (en) | 2012-03-13 | 2013-09-19 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of ovarian cancer |
-
2013
- 2013-03-11 WO PCT/EP2013/054818 patent/WO2013135602A2/en active Application Filing
- 2013-03-11 SI SI201331522T patent/SI2825558T1/sl unknown
- 2013-03-11 AU AU2013231410A patent/AU2013231410B2/en active Active
- 2013-03-11 SG SG11201404417PA patent/SG11201404417PA/en unknown
- 2013-03-11 HU HUE13708435A patent/HUE045445T2/hu unknown
- 2013-03-11 KR KR1020147024773A patent/KR102082363B1/ko active IP Right Review Request
- 2013-03-11 JP JP2014561385A patent/JP6563197B2/ja active Active
- 2013-03-11 CA CA2860941A patent/CA2860941C/en active Active
- 2013-03-11 RS RS20190846A patent/RS58964B1/sr unknown
- 2013-03-11 US US14/384,863 patent/US20150098988A1/en not_active Abandoned
- 2013-03-11 CN CN201380024869.3A patent/CN104334577A/zh active Pending
- 2013-03-11 MX MX2014010591A patent/MX365139B/es active IP Right Grant
- 2013-03-11 BR BR112014018964-1A patent/BR112014018964A2/pt not_active Application Discontinuation
- 2013-03-11 CA CA3056813A patent/CA3056813A1/en not_active Abandoned
- 2013-03-11 PE PE2014001409A patent/PE20141909A1/es not_active Application Discontinuation
- 2013-03-11 LT LTEP13708435.6T patent/LT2825558T/lt unknown
- 2013-03-11 ES ES13708435T patent/ES2736030T3/es active Active
- 2013-03-11 PL PL13708435T patent/PL2825558T3/pl unknown
- 2013-03-11 PT PT13708435T patent/PT2825558T/pt unknown
- 2013-03-11 DK DK13708435.6T patent/DK2825558T3/da active
- 2013-03-11 EA EA201400996A patent/EA201400996A1/ru unknown
- 2013-03-11 SM SM20190389T patent/SMT201900389T1/it unknown
- 2013-03-11 EP EP19174209.7A patent/EP3553083A1/en active Pending
- 2013-03-11 EP EP13708435.6A patent/EP2825558B1/en active Active
- 2013-03-12 AR ARP130100793 patent/AR090313A1/es unknown
- 2013-03-12 TW TW102108775A patent/TW201343178A/zh unknown
-
2014
- 2014-06-27 CO CO14139058A patent/CO7000770A2/es not_active Application Discontinuation
- 2014-06-30 ZA ZA2014/04843A patent/ZA201404843B/en unknown
- 2014-07-03 PH PH12014501543A patent/PH12014501543A1/en unknown
- 2014-08-18 IL IL234174A patent/IL234174B/en active IP Right Grant
- 2014-08-26 CR CR20140400A patent/CR20140400A/es unknown
-
2015
- 2015-03-11 HK HK15102494.0A patent/HK1202122A1/xx unknown
-
2016
- 2016-05-12 US US15/153,637 patent/US11384142B2/en active Active
-
2017
- 2017-11-10 AU AU2017258927A patent/AU2017258927A1/en not_active Abandoned
-
2018
- 2018-07-13 JP JP2018132869A patent/JP6640288B2/ja active Active
- 2018-12-18 IL IL263781A patent/IL263781A/en unknown
-
2019
- 2019-07-11 HR HRP20191248TT patent/HRP20191248T1/hr unknown
- 2019-07-16 CY CY20191100758T patent/CY1121821T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191248T1 (hr) | Kombinirana terapija za liječenje karcinoma jajnika | |
| EA201401028A1 (ru) | Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения | |
| BR112015024678A2 (pt) | inibidor da cinase | |
| BR112015014510A2 (pt) | agonistas de glp1/gip duais ou de glp1/gip/glucagon trigonais | |
| WO2015123576A3 (en) | Targeted nanoparticle compositions and methods of their use to treat obesity | |
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| WO2014058979A3 (en) | Laquinimod for reducing thalamic damage in multiple sclerosis | |
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| BR112014001170A2 (pt) | cateter, especialmente um cateter permanente, para tratamento de problemas funcionais e/ou doenças da bexiga e/ou próstata | |
| RU2015145997A (ru) | Противоопухолевое лекарственное средство, включающее низкодозированный гидрохлорида иринотекана гидрат | |
| BR112014014814A2 (pt) | dispositivo médico | |
| UY35771A (es) | Tienouracil-carboxamidas cíclicas y su uso | |
| Rino et al. | Phase II study on the combination of irinotecan plus cisplatin as a second‑line therapy in patients with advanced or recurrent gastric cancer | |
| HRP20211709T1 (hr) | Antitumorski lijek koji sadrži antitumorski kompleks platine, i pojačivač antitumorskog efekta | |
| RU2011101481A (ru) | Способ профилактики острой декомпрессионной болезни | |
| TH137483A (th) | การรักษาโดยการยับยั้งการเกิดเส้นเลือดใหม่ (anti-angiogenesis therapy) สำหรับบำบัดมะเร็งรังไข่ (ovarian cancer) | |
| RU2012142070A (ru) | Способ восстановительного лечения больных хроническим панкреатитом у работников с вредными условиями труда | |
| Ceruse | Cisplatin/docetaxel/fluorouracil | |
| Samarghandian et al. | Caspase-dependent pathway in apoptosis induced by Safranal in alveolar human lung cancer cell line | |
| 袁嘉敏 | Impact of lymphocytes subgroups in peripheral blood on survival rate of patients with gastric cancer | |
| Mouri et al. | C40 PIERCING THE DARK: ILLUMINATING THE CLINICAL AND BIOLOGICAL CHARACTERISTICS OF LUNG CANCER: Bevacizumab, When Added To Pemetrexed/platinum, Prolongs Survival In Previously Untreated Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer In Japan | |
| PL408781A1 (pl) | Zastosowanie nanocząstek metalicznej platyny | |
| Zhong | Carboplatin/irinotecan | |
| Lazarov et al. | Impact of the ammount of medicaments, administered as adjuvant chemotherapy, over the survival of female patients with early epitelial ovarian cancer | |
| Lin | EFFECT OF FLAG REGIMEN IN TREATMENT OF CHILDREN WITH ACUTE REFRACTORY AND RELAPSED LEUKEMIA |